
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics has demonstrated a favorable growth trajectory with management projecting significant revenue increases for 2026, estimating $167 million in CAR-T sales, which marks a year-over-year growth of approximately 220%. Additionally, the company’s guidance for Aucatzyl revenues between $120 million and $135 million indicates a robust 60-80% year-over-year increase, driven by an expansion of its ATC network to over 80 locations. The positive outlook is further supported by improved sales margins anticipated from increased scale and a historic trend of revenue growth, particularly in light of recent advancements in clinical guidelines favoring bispecific therapies.
Bears say
Autolus Therapeutics PLC exhibits a negative financial outlook due to significant concerns regarding stagnant revenue growth, specifically a nearly 48% decline in stock value since July 2025, in stark contrast to the positive performance of the Nasdaq Biotechnology Index. The company's new product launch, Aucatzyl, faced manufacturing limitations and flat sales during mid-2025, primarily resulting from changes imposed by the Centers for Medicare and Medicaid Services. Additionally, potential risks related to clinical efficacy, safety concerns, regulatory challenges, and anticipated capital needs further exacerbate the financial instability reflected in the company’s performance.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares